*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
Identifying rare disease patient populations via integrated claims data
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...